Table 1.
Baseline characteristics of study participants and changes in these characteristics after the 12-week intervention.
| Placebo Yogurt (n = 64) | OLL2712 Yogurt (n = 62) | |||
|---|---|---|---|---|
| Characteristics | Week 0 | Week 12 | Week 0 | Week 12 |
| Age (years) | 51.2 ± 7.6 | NA | 50.6 ± 6.9 | NA |
| Male/Female | 44/20 | NA | 42/20 | NA |
| BW (kg) | 69.4 ± 12.3 | 70.3 ± 12.5 ** | 69.1 ± 11.0 | 69.8 ± 10.8 ** |
| BMI (kg/m2) | 24.9 ± 3.2 | 25.2 ± 3.4 ** | 24.7 ± 3.3 | 25.0 ± 3.2 ** |
| SBP (mmHg) | 123.3 ± 14.3 | 128.3 ± 14.2 ** | 126.6 ± 14.4 | 133.1 ± 13.2 ** |
| DBP (mmHg) | 74.4 ± 10.7 | 79.7 ± 9.7 ** | 77.4 ± 11.0 | 82.0 ± 11.2 ** |
| HR (beats/min) | 76.4 ± 11.4 | 76.7 ± 12.1 | 76.7 ± 12.2 | 73.8 ± 12.2 * |
Abbreviations: BW, body weight; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; NA, not assessed. Data are presented as means ± standard deviations. Significant differences in measurements compared to those at week 0 (baseline) were determined using the paired t-tests or the Wilcoxon signed-rank tests (* p < 0.05, ** p < 0.01). Significant differences in measurements compared to the placebo group were determined using the unpaired t-test or the Mann–Whitney U tests, and there were no significant differences.